AstraZeneca PLC (AZN)vsBrainsway Ltd (BWAY)
AZN
AstraZeneca PLC
$187.37
+1.17%
HEALTHCARE · Cap: $287.11B
BWAY
Brainsway Ltd
$15.88
-1.37%
HEALTHCARE · Cap: $655.34M
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 112373% more annual revenue ($58.74B vs $52.23M). AZN leads profitability with a 17.4% profit margin vs 14.5%. AZN trades at a lower P/E of 27.9x. AZN earns a higher WallStSmart Score of 64/100 (C+).
AZN
Buy64
out of 100
Grade: C+
BWAY
Hold46
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+4.1%
Fair Value
$214.51
Current Price
$187.37
$27.14 discount
Intrinsic value data unavailable for BWAY.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Earnings expanding 53.9% YoY
Every $100 of equity generates 23 in profit
Strong operational efficiency at 21.6%
Generating 1.4B in free cash flow
Earnings expanding 321.2% YoY
Revenue surging 27.4% year-over-year
Areas to Watch
Expensive relative to growth rate
Moderate valuation
4.1% revenue growth
Distress zone — elevated risk
Trading at 8.5x book value
Smaller company, higher risk/reward
Premium valuation, high expectations priced in
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, EPS Growth, Return on Equity. Profitability is solid with margins at 17.4% and operating margin at 21.6%.
Bull Case : BWAY
The strongest argument for BWAY centers on EPS Growth, Revenue Growth. Revenue growth of 27.4% demonstrates continued momentum.
Bear Case : AZN
The primary concerns for AZN are PEG Ratio, P/E Ratio, Revenue Growth.
Bear Case : BWAY
The primary concerns for BWAY are Price/Book, Market Cap, P/E Ratio. A P/E of 90.9x leaves little room for execution misses.
Key Dynamics to Monitor
AZN profiles as a value stock while BWAY is a growth play — different risk/reward profiles.
AZN carries more volatility with a beta of 0.28 — expect wider price swings.
BWAY is growing revenue faster at 27.4% — sustainability is the question.
AZN generates stronger free cash flow (1.4B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (64/100 vs 46/100), backed by strong 17.4% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Brainsway Ltd
HEALTHCARE · MEDICAL DEVICES · USA
Brainsway Ltd., a commercial-stage medical device company, focuses on the development and sale of non-invasive neuromodulation products in Israel and internationally. The company is headquartered in Jerusalem, Israel.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?